Champions Oncology Inc.

7.43
-0.47 (-5.95%)
Apr 28, 2025, 12:03 PM - Market open
-5.95%
Created with Highcharts 11.4.39 AM4 PM10 AM12 PM1 PM2 PM7.257.57.7588.25
Bid 7.24
Market Cap 102.78M
Revenue (ttm) 58.59M
Net Income (ttm) 6.43M
EPS (ttm) 0.45
PE Ratio (ttm) 16.52
Forward PE 35.59
Analyst Strong Buy
Ask 7.51
Volume 55,042
Avg. Volume (20D) 40,603
Open 7.98
Previous Close 7.90
Day's Range 7.21 - 8.27
52-Week Range 3.60 - 11.99
Beta 0.46

About CSBR

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 2, 2007
Employees 210
Stock Exchange NASDAQ
Ticker Symbol CSBR
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for CSBR stock is "Strong Buy." The 12-month stock price forecast is $12, which is an increase of 61.44% from the latest price.

Created with Highcharts 11.4.3StrongSellSellHoldBuyStrongBuy012
Price Target: $12
(61.44% upside)
Analyst Consensus: Strong Buy
Stock Forecasts
4 months ago
+12.09%
Champions Oncology shares are trading higher after... Unlock content with Pro Subscription
7 months ago
+9.58%
Champions Oncology shares are trading higher after the company reported better-than-expected Q1 financial results. Also, Craig-Hallum upgraded the stock from Hold to Buy and maintained its $6 price target.